Cobra Biologics is a rapidly expanding international contract manufacturing organization (CMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three good manufacturing practice (GMP)-approved facilities, each with expertise tailored to serving our customers across the world. We offer a broad range of integrated and stand-alone contract services, stretching from cell line and process development through to fill and finish for the supply of investigational medicinal products and commercial production.
Experience
For over 16 years, we have taken pride in being a trusted manufacturing provider, delivering what we promise and helping our customers to develop medicines for the benefit of patients. Cobra provides manufacturing technologies, platforms, and solutions to the biopharmaceutical industry covering antibodies, recombinant proteins, viruses, phage, DNA, whole-cell vaccines and therapeutics as well as biologics and small-molecule active pharmaceutical ingredient (API) lyophilization and fill–finish.
Cobra’s MaxXpress service optimizes cell-line development using a unique technology that infuses Ubiquitous Chromatin- Opening Element (UCOE) technology with cell-line development expertise to yield increased recombinant protein and antibody production. This technology can be used to produce 100–300 mg of material in under 10 weeks.
Cobra uses Ambr™ micro bioreactor technology (from TAP Biosystems) to evaluate process parameters. The better monitoring, process control capability, and speed (weeks not months) — compared with shake-flask culture or bioreactors — are significant advantages and allow data about the cells’ behavior and product characteristics to be collected before larger bioreactor studies. This ensures superior product similarity to that achieved in a large-scale bioreactor.
Excellence
At Cobra, we recognize the value of transparent and effective communications with our customers. We ensure that we provide regular progress updates as well as respond to our customers’ needs. Large enough to deliver and small enough to care, Cobra dedicates the attention and resources needed with multidisciplinary teams that remain with each program throughout its life. This seamless integration reduces both transfer risk and time delays, thereby increasing customer satisfaction. Delivering the highest quality products on schedule through trusted relationships ensures that our customers come back for further clinical development and production or with new projects.
Find out more, take a virtual tour and get in touch with our expert team today: www.cobrabio.com.
Jason Rahal is senior vice president of business development, North America, 500 N. Michigan Ave., Suite 600, Chicago, IL 60611; 1-773- 478-5334; jason.rahal@cobrabio.com; www.cobrabio.com.